Regulating Human Embryonic Stem Cell in China

Zusatztext

The general scope of the book is the patentability and morality of human embryonic stem cell research in US, EU and China. The book observes fraudsters operate unsafe human embryonic stem cell therapies and officialdom turns a blind eye to the immoral human embryonic stem cell research in China. The book highlights that both patent control and federal funding control are inefficient and ineffective way to monitoring human embryonic stem cell research.  The book finally proposed an approach for china to regulating human embryonic stem cell research-regulating research itself at the reconciled international regime.  The potential reader includes academics and practitioners dealing with intellectual property, patent law and stem cell inventions.  The topic discussed will also be interesting to a broad readership, including experts, regulators, policy makers and medical researchers in both ethical and legal disciplines in the field of embryonicstem cell research.

Autorenportrait

Li Jiang is currently a lecturer in Kenneth Wang School of Law, Soochow University. Born in China, Li Jiang was educated at Shandong University, China and graduated with a Bachelors degree in Biotechnology. Li Jiang gained her PhD degree at Bangor University Law School in 2014. Jiangs research looks at the scope of patentability in respect of the application of the moral exclusion to human embryonic stem cell research through a comparative analysis of the diverging interpretations which have emerged in the regulations of US, EU and China. Many pieces of Jiangs work have been published by leading international journals in Australia and the United States.

Weitere Details